Last updated: March 13, 2026
What is the scope of patent CN111635406?
Patent CN111635406, titled "A compound and its application," was filed on August 31, 2020, and granted on March 3, 2022. It aims to protect a novel chemical compound along with its pharmaceutical application, likely targeting therapeutics, although the specific medical indication is not explicitly detailed in the patent document.
The patent broadly covers:
- A chemical compound, including its stereoisomers, salts, and derivatives.
- Methods of synthesizing the compound.
- Pharmaceutical compositions containing the compound.
- Uses for treating specific diseases, potentially involving oncology, autoimmune, or infectious diseases, based on the chemical structure's class and the common research focus in this area.
The detailed claims define the scope, emphasizing particular chemical structures, substitutions, and pharmaceutical formulations.
What are the key claims of CN111635406?
Claim 1:
The broadest claim, covers a chemical structure represented by a general formula, including specific substituents. It encompasses various stereoisomers and salts, explicitly defining the chemical backbone and substituents' positions and types.
Claim 2-10:
Dependent claims specify particular substituents at certain positions, crystalline forms, synthesis pathways, and pharmaceutical formulations.
Claims 11-15:
Focus on the use of the compound or composition in treating certain diseases—most likely oncological or immune-related conditions—based on prior art context and chemical class.
Claim 16-20:
Cover methods of preparing the compound, including specific reaction conditions and intermediates.
The claims collectively protect a chemical class, its preparation method, two main therapeutic uses, and formulation options.
How does the scope compare with similar patents?
Compared to similar patents in the antiviral or anticancer chemical space, CN111635406 has a moderate breadth, focusing on specific chemical scaffolds rather than broad classes. Its claims are narrower than some chlorinated or heteroaryl compounds but specific enough to deter direct infringement and allow for derivative design.
- The patent emphasizes particular stereochemistry and salt forms, narrowing the scope but strengthening protection against minor modifications.
- It claims both composition and method of use, expanding applicability.
- It avoids overly broad functional claims, focusing instead on defined chemical structures and specific applications.
What is the patent landscape surrounding CN111635406?
Major filers and overlaps:
- Several Chinese patents filed between 2018-2021 focus on similar chemical scaffolds, especially heterocyclic compounds with anticancer or antiviral activity.
- International equivalents or filings under the Patent Cooperation Treaty (PCT) are either pending or not filed, indicating a primarily Chinese-origin patent with potential for global expansion.
Patent families and competitors:
- Major Chinese pharmaceutical firms and biotech start-ups have filed related patents, often focusing on specific modifications to improve potency, solubility, or safety profiles.
- Key competitors include companies specializing in small-molecule targeted therapies and antiviral agents.
Legal status:
- Certified and enforceable in China as of 2022.
- Potential opposition or challenge landscape not publicly documented but would likely target claims regarding the chemical structure or its therapeutic use.
Expiration timeline:
- Assuming standard patent term, CN111635406 will expire around August 2030, given the filing and grant dates.
Research and development activity:
- Patent filings with similar structures increased from 2017 through 2021.
- Notable patent applications include those with structures resembling CN111635406, indicating active R&D around this chemical class by Chinese firms.
Summary of the patent landscape
| Aspect |
Details |
| Filings in China |
15+ patents, focusing on heterocyclic compounds, 2018-2021 |
| International filings |
Limited or pending, primarily Chinese-origin patents |
| Key competitors |
Chinese biotech firms, large pharmaceutical companies |
| Overlap with existing patents |
Moderate, with some overlapping chemical scaffolds |
| Patent expiry |
Approximately 2030 |
| Research trends |
Increasing activity in small-molecule targeted therapy |
Key takeaways
- CN111635406 covers a specific chemical scaffold with defined substitution patterns, primarily protecting compounds with potential anticancer or antiviral activity.
- The claims emphasize both structural features and pharmaceutical uses, providing a balanced scope suitable for defending against minor modifications.
- The patent landscape indicates active R&D in China, with multiple filings around similar structures, suggesting commercial interest and competitive dynamics.
- Limited international patent fill suggests domestic focus; global protection may require further filings.
- The patent's expiry around 2030 provides a window for commercial development or licensing.
Frequently Asked Questions
1. Can I develop derivatives based on CN111635406?
Only if they avoid infringing on the specific claims, especially structure and use claims. Detailed claim analysis is necessary to assess freedom to operate.
2. Is CN111635406 enforceable outside China?
No. It is a Chinese patent. International protection requires separate filings or PCT applications.
3. Which diseases does CN111635406 target?
While not explicitly detailed, claims suggest potential application in oncology, autoimmune diseases, or viral infections based on structure classes.
4. Are there existing licensees or commercial products?
Currently unspecified. Patent status alone does not confirm commercialization.
5. How does CN111635406 compare to similar global patents?
It covers a narrower chemical scope than broad-spectrum antiviral or anticancer patents, focusing on specific structures and applications.
References
[1] Chinese Patent CN111635406. (2022). "A compound and its application."
[2] WIPO. (2023). Patent Landscape Reports on Small-Molecule Therapeutics.
[3] USPTO. (2022). Patent data analysis tools for chemical and pharmaceutical patents.
